Could a 7-Day cocktail beat h. pylori? new trial tests shorter fix

NCT ID NCT07232095

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 7-day combination of vonoprazan, high-dose amoxicillin, and bismuth can effectively eradicate H. pylori bacteria in the stomach. About 316 adults with a first-time H. pylori infection will be randomly assigned to either the 7-day triple therapy or a standard 14-day dual therapy. The goal is to see if the shorter regimen works just as well with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vonoprazan, Amoxicillin, and Bismuth
What this could lead to: If successful, this 7-day triple therapy could offer a shorter, effective first-line treatment for H. pylori infection, potentially improving patient compliance.
What could go wrong: This is a phase 4 trial, but the shorter regimen may still fail to achieve adequate eradication rates, and bismuth can cause side effects like dark stools or nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI

Contacts and locations

Locations

The First Affiliated Hospital with Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.